 | |  | |  | |  | |  | |  | |  | |  |
| IJCEM Copyright © 2008-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Int J Clin Exp Med 2010;3(3):192-201
Review Article
Drug-eluting stents
Xiaodong Ma, Tim Wu, Michael P.Robich, Xingwei Wang, Hao Wu, Bryan Buchhloz, Stephen McCarthy
Biomedical Engineering and Biotechnology Doctoral Program， University of Massachusetts, Lowell, MA 01854, USA; VasoTech, Inc.,
Lowell, MA 01854, USA; Department of Surgery, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard
Medical School, Boston, MA 02215, USA.
Received May 25, 2010, accepted June 20, 2010, available online June 25, 2010
Abstract: Coronary artery disease (CAD) is currently a leading cause of death worldwide. Drug-eluting stents (DESs) have been
dominant for the treatment of CAD in the interventional cardiology world owing to their efficacy in significantly reducing restenosis.
However, late stage stent thrombosis has become a major concern. Stent platform, drug delivery vehicle and type of drug are three
parts of DES and each part affects the performance of the DES. Aiming to provide a clue for the design of future DES, this review
focuses on the development of the three major components of DES and their roles in restenosis and thrombosis. (IJCEM1005004).
Key words: Drug-eluting stents, restenosis, thrombosis
Full Text PDF
Address all correspondence to:
Tim Wu, MD
VasoTech, Inc., 333 Aiken Street
Lowell, MA 01854.
Tel: 617-686-2770; Fax: 617-446-1518
Email: tiangenwu@yahoo.com.
Review Article
Drug-eluting stents
Xiaodong Ma, Tim Wu, Michael P.Robich, Xingwei Wang, Hao Wu, Bryan Buchhloz, Stephen McCarthy
Biomedical Engineering and Biotechnology Doctoral Program， University of Massachusetts, Lowell, MA 01854, USA; VasoTech, Inc.,
Lowell, MA 01854, USA; Department of Surgery, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Harvard
Medical School, Boston, MA 02215, USA.
Received May 25, 2010, accepted June 20, 2010, available online June 25, 2010
Abstract: Coronary artery disease (CAD) is currently a leading cause of death worldwide. Drug-eluting stents (DESs) have been
dominant for the treatment of CAD in the interventional cardiology world owing to their efficacy in significantly reducing restenosis.
However, late stage stent thrombosis has become a major concern. Stent platform, drug delivery vehicle and type of drug are three
parts of DES and each part affects the performance of the DES. Aiming to provide a clue for the design of future DES, this review
focuses on the development of the three major components of DES and their roles in restenosis and thrombosis. (IJCEM1005004).
Key words: Drug-eluting stents, restenosis, thrombosis
Full Text PDF
Address all correspondence to:
Tim Wu, MD
VasoTech, Inc., 333 Aiken Street
Lowell, MA 01854.
Tel: 617-686-2770; Fax: 617-446-1518
Email: tiangenwu@yahoo.com.
